Formulation and in vitro evaluation of bilayer floating tablets of metformin hydrochloride and sitagliptin phosphate
Abstract
The main aim of present study is to formulate and evaluate bilayer tablets of Metformin Hydrochloride and Sitagliptin Phosphate as fixed dose combination tablets for effective treatment of type II diabetes mellitus. Here, an attempt was made to reduce the dose, dosage frequency, dose related gastrointestinal side effects of metformin and to improve its bioavailability which in turn improve the patient compliance. Preformulation studies including drug excipient compatibility were conducted for both drugs. Different formulations of sustained release, floating Metformin Hcl tablets were prepared by using hydrophilic polymers like HPMC K100 and Sodium CMC and were evaluated. Sitagliptin immediate release formulations were prepared using crosspovidone, croscarmellose sodium and sodium starch glycolate as superdisintegrants and were evaluated. Based on the in vitro dissolution data F7 and S9 were selected as the best formulations from Metformin and Sitagliptin formulations respectively. Bilayer tablets were prepared by slightly compressing Metformin layer (F7) and then final compression was made by placing Sitagliptin layer (S9) layer on it with final hardness 6.5 kg and they were evaluated. From the bilayer tablet Sitagliptin layer disintegrated in 52 sec, Metformin layer started floating after 5.2 min and gave total floating time 18-24 hrs with good swelling index, good post compression parameters. In vitro dissolution study of bilayer tablet was done in USP type II along with…
How strong is the evidence?
Evidence Hub reads this as a thesis, done in cell cultures (in vitro), not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.